Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23826475 | 0.89 | HTR2C (0.50) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL25841627 | 0.85 | HTR2C (0.59) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL28411733 | 0.85 | HTR2C (0.59) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL29936064 | 0.85 | HTR2C (0.53) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL29936364 | 0.85 | HTR2C (0.53) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL3240363 | 0.85 | HTR2C (0.53) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL384788 | 0.85 | HTR2C (0.53) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL24179626 | 0.85 | HTR2C (0.53) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL27128101 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL26984283 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457296-B | Pyrimidine compound and preparation method thereof | 武汉人福创新药物研发中心有限公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-4029858-A1 | PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-20220204479-A1 | PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2022-06-30 | — | — | US | disclosed |
| WO-2021043260-A1 | PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR | 湖北生物医药产业技术研究院有限公司 | 2021-03-11 | — | — | WO | disclosed |
| CN-112457296-A | Pyrimidine compound and preparation method thereof | 湖北生物医药产业技术研究院有限公司 | 2021-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204479-A1 | PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR | TYMP, DPYD, TYMS | HTR2C 2530/4885PDK1 1593/4885PDK2 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.